Dmytro Shymkiv: Darnitsa Launched an Online Project about Post-COVID Syndrome

Darnitsa, pharmaceutical company, has created an online platform for collecting official information about post-COVID syndrome: various side effects that those who have had a Coronavirus disease can experience.

According to Dmytro Shymkiv, Head of the Board of Directors, the goal of the project is to collect all available information about post-COVID syndrome and analyse it to subsequently make it known to citizens.

According to the National Institute for Health and Care Excellence, almost half of people who have had COVID-19 may have post-COVID syndrome. It is expressed in certain symptoms that are observed within three months after the disease, and in some cases, even longer.

Physicians distinguish among these symptoms shortness of breath and trouble breathing (77% of those who have recovered), increased heart rate and chest pain (up to 67%), general fatigue, and unreasonable fear and anxiety (from 40 to 80%).

In addition to general information, the online platform contains a number of recommendations for overcoming the consequences of COVID-19, including advice on planning a daily routine, breathing and relaxation techniques.

At the same time, according to Shymkiv, all recommendations are based solely on the results of international expert studies.

Ihor Nikiforchyn, Darnitsa Medical Director, agrees with Dmytro Shymkiv believing that free access to complete and up-to-date information about COVID-19 and post-COVID syndrome is a prerequisite for successfully combating the pandemic and its negative consequences.

‘We are the leaders of the pharmaceutical market in Ukraine, therefore, we certainly cannot ignore the most pressing issue in the healthcare sector. Caring for doctors and patients is our mission’, Nikiforchyn emphasized.

Darnitsa, pharmaceutical company, was founded in 1930. The company’s portfolio includes over 210 brands of medicines. The enterprise has 14 GMP certified production lines. The products of Darnitsa are exported to 16 countries of the world. The beneficiaries of the company are the Zahorii family.